bipsai← Research library

Today's Lens

Today's Lens: Celldex Therapeutics, Inc. (CLDX)

Celldex Therapeutics, Inc. · NASDAQ · Equity · Stock

US market session 2026-09-22 · Analysis as of September 22, 2026 at 12:00 AM UTC.

The synthesis

Positive Phase 3 clinical data for barzolvolimab offset by extreme operational losses and potential for future equity dilution.

68%bullish lean
+Bull case
  1. Late-stage clinical success

    Barzolvolimab met all primary and key secondary endpoints in Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials for chronic spontaneous urticaria (8-K, 2026-09-22).

  2. Extended liquidity runway

    Per the 10-Q, current cash and marketable securities of $717.6 million are sufficient to fund planned operations through 2028.

  3. Growing institutional support

    Engineers Gate Manager LP recently established a new $1.26 million position, signaling professional confidence following successful clinical readouts.

−Bear case
  1. Severe operational deficits

    The company reported a significant increase in net loss, with operating margins at -290,948% driven by escalating R&D expenses (10-Q, 2026-08-06).

  2. Pipeline development risks

    Barzolvolimab failed its Prurigo Nodularis study, suggesting mast cells may not be the key pathogenic driver for all targeted indications.

  3. Imminent dilution risk

    Management notes that additional equity financings may be 'dilutive to our stockholders' to meet long-term capital needs (10-Q, MD&A).

Catalysts

  • Full Phase 3 data presentation Near-term
  • Barzolvolimab BLA filing 2027
  • CIndU re-treatment data Ongoing
  • CDX-622 pipeline advancement Q4

Risks

  • Equity dilution High probability
  • R&D expense growth +$16.9M YoY
  • Regulatory approval FDA pending
  • Technical support breach $32.18 level

What would change the view

A sustained break above the 50-day moving average of $39.10 paired with a formal BLA submission would strengthen the bull case. Conversely, a breach of the 200-day support at $32.18 or an unannounced dilutive equity offering would validate bear concerns regarding liquidity and momentum.

Insider activity

Open-market purchases and sales reported by company insiders on SEC Form 4, from EDGAR. Share counts and dates only.

Trailing 3 months: 0 open-market purchases by 0 insiders and 0 sales by 0 insiders. Balanced.

Sources

  1. FMP · CLDX daily prices and technical indicators Analyst note
  2. FMP · CLDX financial statements (income / balance / cash flow) SEC filing
  3. SEC EDGAR · CLDX full-text filing search SEC filing
  4. SEC · 8-K filed 2026-09-22 (Items 8.01, 9.01) SEC filing · 8-K · 2026-09-22
  5. SEC · SCHEDULE 13G/A filed 2026-08-14 SEC filing · SCHEDULE 13G/A · 2026-08-14
  6. SEC · SCHEDULE 13G filed 2026-08-14 SEC filing · SCHEDULE 13G · 2026-08-14
  7. SEC · 10-Q filed 2026-08-06 SEC filing · 10-Q · 2026-08-06
  8. SEC · 8-K filed 2026-08-06 (Items 2.02, 9.01) SEC filing · 8-K · 2026-08-06
  9. SEC · 8-K filed 2026-07-15 (Items 5.02, 9.01) SEC filing · 8-K · 2026-07-15
  10. SEC · 4 filed 2026-06-29 SEC filing · 4 · 2026-06-29
  11. SEC · 4 filed 2026-06-29 SEC filing · 4 · 2026-06-29
  12. SEC · 4 filed 2026-06-29 SEC filing · 4 · 2026-06-29
  13. SEC · 4 filed 2026-06-29 SEC filing · 4 · 2026-06-29
  14. SEC · 4 filed 2026-06-29 SEC filing · 4 · 2026-06-29
  15. SEC · 4 filed 2026-06-29 SEC filing · 4 · 2026-06-29
  16. SEC · 4 filed 2026-06-29 SEC filing · 4 · 2026-06-29
  17. SEC · 4 filed 2026-06-29 SEC filing · 4 · 2026-06-29
  18. SEC · 4 filed 2026-06-29 SEC filing · 4 · 2026-06-29
  19. SEC · 4 filed 2026-06-29 SEC filing · 4 · 2026-06-29
  20. SEC · 4 filed 2026-06-29 SEC filing · 4 · 2026-06-29
  21. SEC · 4 filed 2026-06-29 SEC filing · 4 · 2026-06-29
  22. SEC · 4 filed 2026-06-29 SEC filing · 4 · 2026-06-29
  23. SEC · 4 filed 2026-06-29 SEC filing · 4 · 2026-06-29
  24. SEC · 4 filed 2026-06-29 SEC filing · 4 · 2026-06-29
  25. SEC · 4 filed 2026-06-29 SEC filing · 4 · 2026-06-29
  26. SEC · 4 filed 2026-06-29 SEC filing · 4 · 2026-06-29
  27. SEC · 4 filed 2026-06-29 SEC filing · 4 · 2026-06-29
  28. SEC · S-8 filed 2026-06-26 SEC filing · S-8 · 2026-06-26
  29. SEC · 8-K filed 2026-06-26 (Items 5.02, 5.07, 9.01) SEC filing · 8-K · 2026-06-26
  30. Reuters · Celldex's skin disease drug meets goals in two late-stage trials News
  31. GlobeNewsWire · Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary a News
  32. Defense World · Head-To-Head Survey: Celldex Therapeutics (NASDAQ:CLDX) & Bicycle Therapeutics (NASDAQ:BCYC) News
  33. Defense World · Engineers Gate Manager LP Takes $1.26 Million Position in Celldex Therapeutics, Inc. $CLDX News

Read the full analysis in the app

This page publishes the written thesis. The app adds the sections not published here:

  • Fundamentals
  • Technicals
  • News with bull, bear, and neutral tags
  • 7-day news sentiment and earnings-call tone
  • Forward analyst estimates
  • Earnings-call summary
Download bips·ai on the App StoreGet bips·ai on Google Play